作者
Qingyang Shi, Kailei Nong, Per Olav Vandvik, Gordon H Guyatt, Oliver Schnell, Lars Ryden, Nikolaus Marx, Frank C Brosius, Reem A Mustafa, Arnav Agarwal, Xinyu Zou, Yunhe Mao, Aminreza Asadollahifar, Saifur Rahman Chowdhury, Chunjuan Zhai, Sana Gupta, Ya Gao, João Pedro Lima, Kenji Numata, Zhi Qiao, Qinlin Fan, Qinbo Yang, Yinghui Jin, Long Ge, Qiuyu Yang, Hongfei Zhu, Fan Yang, Zhe Chen, Xi Lu, Siyu He, Xiangyang Chen, Xiafei Lyu, Xingxing An, Yaolong Chen, Qiukui Hao, Eberhard Standl, Reed Siemieniuk, Thomas Agoritsas, Haoming Tian, Sheyu Li
发表日期
2023/4/6
来源
Bmj
卷号
381
出版商
British Medical Journal Publishing Group
简介
Objective
To compare the benefits and harms of drug treatments for adults with type 2 diabetes, adding non-steroidal mineralocorticoid receptor antagonists (including finerenone) and tirzepatide (a dual glucose dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist) to previously existing treatment options.
Design
Systematic review and network meta-analysis.
Data sources
Ovid Medline, Embase, and Cochrane Central up to 14 October 2022.
Eligibility criteria for selecting studies
Eligible randomised controlled trials compared drugs of interest in adults with type 2 diabetes. Eligible trials had a follow-up of 24 weeks or longer. Trials systematically comparing combinations of more than one drug treatment class with no drug, subgroup analyses of randomised controlled trials, and non-English language studies were deemed ineligible. Certainty of evidence was assessed following …
学术搜索中的文章
Q Shi, K Nong, PO Vandvik, GH Guyatt, O Schnell… - Bmj, 2023